Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630719 · ClinicalTrials.gov registry record · NA
Timolol Eye Drops in the Treatment of Acute Migraine Headache
A NA study, sponsored by University of Missouri, Kansas City.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02630719 is a NA study that was terminated before completion, run by University of Missouri, Kansas City. The registered enrollment target is 10 participants.
The verdict
NCT02630719, a NA study, was terminated before completion, sponsored by University of Missouri, Kansas City.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.
Interventions
- DRUG Artificial tears
- DRUG Timolol eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-08-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02630719
The ClinicalTrials.gov registry entry for NCT02630719 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri, Kansas City, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Artificial tears is the first listed.
NCT02630719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02630719 about?
NCT02630719 is a clinical study titled "Timolol Eye Drops in the Treatment of Acute Migraine Headache". The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.
What is the current status of trial NCT02630719?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2016-01. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT02630719?
The interventions under investigation include: Artificial tears (DRUG), Timolol eye drops (DRUG).
Who is sponsoring clinical trial NCT02630719?
This trial is sponsored by University of Missouri, Kansas City, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.